@article {Yang:2007:1172-7047:417,
	author = "Yang, Lily P.H.",
	author = "Plosker, Greg L.",
	title = "Paliperidone Extended Release",
	journal = "CNS Drugs",
	volume = "21",
	year = "2007",
	abstract = "&#9652; Paliperidone extended release (ER) is an atypical antipsychotic that is administered orally once daily to provide consistent plasma drug concentrations over 24 hours in adult patients with schizophrenia.<P></P>&#9652; In four well controlled trials, once-daily administration of paliperidone ER 3-12mg over 6 weeks was more effective than placebo in reducing the positive and negative symptoms experienced by adult patients with schizophrenia, including elderly individuals aged &#8805;65 years.<P></P>&#9652; Patients with schizophrenia treated with paliperidone ER achieved greater improvement in clinically relevant measures of personal and social functioning and disease severity than those who received placebo.<P></P>&#9652; In another well controlled trial, paliperidone ER demonstrated superior efficacy to placebo in preventing the recurrence of schizophrenia symptoms. In patients who experienced a recurrence, time to recurrence was delayed with paliperidone ER compared with placebo administration.<P></P>&#9652; Paliperidone ER 3-12 mg/day for 6 weeks was generally well tolerated by patients with schizophrenia in clinical trials.",
	pages = "417-425(9)",
	url = "http://www.ingentaconnect.com/content/adis/cns/2007/00000021/00000005/art00005"
}